Publication:
Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section

dc.contributor.authorTavazzi, Guido
dc.contributor.authorRosselló, Xavier
dc.contributor.authorGrand, Johannes
dc.contributor.authorGierlotka, Marek
dc.contributor.authorSionis, Alessandro
dc.contributor.authorAhrens, Ingo
dc.contributor.authorHassager, Christian
dc.contributor.authorPrice, Susanna
dc.date.accessioned2024-10-04T13:22:47Z
dc.date.available2024-10-04T13:22:47Z
dc.date.issued2022-09-29
dc.descriptionThis is a postprint (Accepted Manuscript) of an article published by Oxford in European Heart Journal. Acute Cardiovascular Care on 2022 September 29, available online: https://doi.org/10.1093/ehjacc/zuac087
dc.description.abstractAims: Cardiogenic shock (CS) is a life-threatening condition burdened by mortality in up to 50% of cases. Few recommendations exist with intermediate-low level of evidence on CS management and no data on adherence across centres exist. We performed a survey to frame CS management at multinational level. Methods and results: An international cross-sectional survey was created and approved by European Society of Cardiology-Acute Cardiovascular Care Association board. A total of 337 responses from 60 countries were obtained. Data were assessed by the hospital level of care of the participants. The most common cause of CS was AMI (AMI-CS-79.9%) with significant difference according to hospital levels (P = 0.001), followed by acutely decompensated heart failure (HF) (13.4%), myocarditis (3.5%), and de novo HF (1.75%). In 37.8%, percutaneous coronary intervention (PCI) is performed to all CS-patients as a standard approach, whereas 42.1% used PCI if electrocardiogram suggestive of ischaemia and 20.1% only if Universal definition of myocardial infarction criteria are fulfilled. Management (catecholamine titration and mechanical circulatory support escalation) is driven by mean arterial pressure (87.1%), echocardiography (84.4%), and lactate levels (83.4%). Combination of vasopressor and inotrope is chosen with the same frequency (37.7%) than inotrope alone as first-line pharmacological therapy (differences amongst hospital levels; P > 0.5). Noradrenaline is first-line vasopressor (89.9%) followed by dopamine (8.5%), whereas dobutamine is confirmed as the first-line inotrope (65.9%). Conclusion: Cardiogenic shock management is heterogenous and often not adherent to current recommendations. Quality improvement on an international level with evidence-based quality indicators should be developed to standardize diagnostic and therapeutic pathways.en
dc.format.number9es_ES
dc.format.page706es_ES
dc.format.volume11es_ES
dc.identifier.citationTavazzi G, Rossello X, Grand J, Gierlotka M, Sionis A, Ahrens I, et al. Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section. Eur Hear Journal Acute Cardiovasc Care. 2022 Sep 29;11(9):706-11.en
dc.identifier.doi10.1093/ehjacc/zuac087
dc.identifier.e-issn2048-8734es_ES
dc.identifier.journalEuropean heart journal. Acute cardiovascular carees_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/18600
dc.identifier.pubmedID35941730es_ES
dc.identifier.puiL638690058
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23429
dc.identifier.wos837522700001
dc.language.isoengen
dc.publisherOxford University Press
dc.relation.publisherversionhttps://doi.org/10.1093/ehjacc/zuac087en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.decsNorepinefrina*
dc.subject.decsDopamina*
dc.subject.decsResultado del Tratamiento*
dc.subject.decsEstudios Transversales*
dc.subject.decsHumanos*
dc.subject.decsIntervención Coronaria Percutánea*
dc.subject.decsDobutamina*
dc.subject.decsLactatos*
dc.subject.decsChoque Cardiogénico*
dc.subject.meshDobutamine*
dc.subject.meshTreatment Outcome*
dc.subject.meshShock, Cardiogenic*
dc.subject.meshHumans*
dc.subject.meshNorepinephrine*
dc.subject.meshDopamine*
dc.subject.meshCross-Sectional Studies*
dc.subject.meshLactates*
dc.subject.meshPercutaneous Coronary Intervention*
dc.titleEpidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research sectionen
dc.typeresearch articleen
dc.type.hasVersionSMURes_ES
dspace.entity.typePublication
relation.isPublisherOfPublication465a0b1e-d9df-4342-b738-86ffcafc4bcf
relation.isPublisherOfPublication.latestForDiscovery465a0b1e-d9df-4342-b738-86ffcafc4bcf

Files